comparemela.com

Latest Breaking News On - Ubiquigent limited - Page 1 : comparemela.com

Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432

Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Ubiquigent and Debiopharm enter agreement to support USP1 inhibitor programme for Debio 0432

Ubiquigent and Debiopharm enter agreement to support USP1 inhibitor programme for Debio 0432
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.

Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics

Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics.

Ubiquigent collaborates with Imperial College London on DUB probe discovery to facilitate preclinical and clinical target engagement studies

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a PhD student in the Institute of Chemical Biology EPSRC Centre for Doctoral Training (CDT) in Chemical Biology, at Imperial College London.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.